AbbVie Inc. (ABBV)
AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript
AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript
AbbVie (ABBV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AbbVie (ABBV) Tops Q4 Earnings and Revenue Estimates
AbbVie (ABBV) came out with quarterly earnings of $2.71 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.16 per share a year ago.
AbbVie Revenue Rises on Immunology Growth
AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio, led by arthritis and Crohn's disease drugs Skyrizi and Rinvoq.
Buy AbbVie Stock Before Q4 Earnings? Here's What to Know
ABBV heads into Q4 earnings with Skyrizi and Rinvoq driving growth, Humira sales sliding, and shares trading at a discount to the industry.
Wall Street Week Ahead
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Stay Ahead of the Game With AbbVie (ABBV) Q4 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
10 Highest Rated Dividend Kings For Generations Of Income
My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend safety/growth grades, and favorable Quant, SA, and Wall Street ratings. ABM Industries leads with a low 31% payout ratio, 2.5% yield, B- safety/growth, and an A- valuation grade despite a Hold Quant rating.
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in AbbVie Stock?
Investors need to pay close attention to ABBV stock based on the movements in the options market lately.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Best Dividend Kings: January 2026
Dividend Kings underperformed SPY in 2025, averaging 4.91% total return versus SPY's 17.72%, though 14 Kings outperformed the index. 2026 began strongly for Dividend Kings, up 4.66% through January 23rd, outpacing SPY's 1.07% gain. Nineteen Dividend Kings appear both potentially undervalued and offer long-term annualized expected returns of at least 10%.
